The shared services Core will synthesize sialic acid containing ligands of siglecs that are needed for the projects of the Lung Inflammatory Disease- Program of Excellence in Glycosciences (LID-PEG) and other PEGs. The core will accomplish its goals using chemo-enzymatic synthesis technology assembled and in routine use in the Core Leader's laboratory. Compounds targeted for synthesis in the first year will be those needed by the LID-PEG projects. Envisioned applications of the compounds include: 1) assaying the ligand binding activity of recombinant siglec reagents, 2) development of siglec-ligand decorated nanoparticles for targeting leukocytes expressing the corresponding siglec, 3) isolation of siglec counter- receptors, and 4) use as standards for MS/MS identification of glycan fragments related to siglec ligands. The Core will also synthesize compounds to meet the needs of other PEGs, and will engage in collaborative synthesis with carbohydrate chemistry groups within the PEGs for products that can benefit from the Core technology. The Executive Committee of the LID-PEG will periodically review and prioritize the list of glycans to be produced by the Shared Resources Core C. Once produced, compounds will be distributed to the LID-PEG and other PEG projects upon request. Compounds will also be made available to investigators outside the PEGs. The list of compounds available from the Core will be posted online at the LID-PEG web site and (preferably) also at the central PEG website.

Public Health Relevance

This shared resource core will synthesize carbohydrates that are recognized by receptors on immune cells. Nanoparticles decorated with these compounds can carry cargo to immune cells for diagnosis and treatment of inflammatory diseases of the lung and cardiovascular system

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-H)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
O'Sullivan, Jeremy A; Bochner, Bruce S (2017) Eosinophils and eosinophil-associated diseases: An update. J Allergy Clin Immunol :
Yu, Huifeng; Gonzalez-Gil, Anabel; Wei, Yadong et al. (2017) Siglec-8 and Siglec-9 binding specificities and endogenous airway ligand distributions and properties. Glycobiology 27:657-668
O'Sullivan, Jeremy A; Carroll, Daniela J; Cao, Yun et al. (2017) Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells. J Allergy Clin Immunol :
Carroll, Daniela J; O'Sullivan, Jeremy A; Nix, David B et al. (2017) Sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8) is an activating receptor mediating ?2-integrin-dependent function in human eosinophils. J Allergy Clin Immunol :
Guo, Hongbo; de Vries, Erik; McBride, Ryan et al. (2017) Highly Pathogenic Influenza A(H5Nx) Viruses with Altered H5 Receptor-Binding Specificity. Emerg Infect Dis 23:220-231
Lou, Hongfei; Lu, Jingning; Choi, Eun Byul et al. (2017) Expression of IL-22 in the Skin Causes Th2-Biased Immunity, Epidermal Barrier Dysfunction, and Pruritus via Stimulating Epithelial Th2 Cytokines and the GRP Pathway. J Immunol 198:2543-2555
Peng, Wenjie; Paulson, James C (2017) CD22 Ligands on a Natural N-Glycan Scaffold Efficiently Deliver Toxins to B-Lymphoma Cells. J Am Chem Soc 139:12450-12458
Schnaar, Ronald L; Lee, Yuan C (2017) Discoveries of the structures of sialic acid and CMP-sialic acid (1957-1960): A letter from Saul Roseman. Glycobiology :
Wu, Nicholas C; Xie, Jia; Zheng, Tianqing et al. (2017) Diversity of Functionally Permissive Sequences in the Receptor-Binding Site of Influenza Hemagglutinin. Cell Host Microbe 21:742-753.e8
Schleimer, Robert P; Schnaar, Ronald L; Bochner, Bruce S (2016) Regulation of airway inflammation by Siglec-8 and Siglec-9 sialoglycan ligand expression. Curr Opin Allergy Clin Immunol 16:24-30

Showing the most recent 10 out of 65 publications